Marv, I and others have been on this board for years, and in TPIV for years and have engaged in constructive and factual banter.
I am trying to figure out your agenda, because as a seasoned investor for many years, I understand that rarely if ever an investment will deliver on given “timelines”. You do not seem to appreciate the science [which is the crux of our investment]
I like yourself and others, am not satisfied with the delayed timelines in execution, but most of it is not due to Glynn.
The Mayo clinic has most of that power, and they are notorious for not meeting timelines. TPIV is not their only project, and they have much red tape to maneuver . They held up the initial Phase 1 data, and are now holding up the final data as well. Glynn has no power over those decisions.
I am trying to understand your obsession with his removal, for in my 7 years as a TPIV investor although the timeframes seem to be delayed at times, I for one appreciate the fact that he is true to not pumping the stock, and lets the science speak for itself.
I understand your frustration but believe that it is misguided, Glynn has taken TPIV from a speculative entity, and transformed it into a viable company, with a very viable product. Anyone investing in Bio Tech [albeit the traders] knows that the time line to bring a new drug to market, falls into the 11 year range. We are at about , at the longest 7/8 years of an actual real company.
And we will know if TPIV holds a viable vaccine within the next 18 months, within that timeframe, they will either be bought out, or merged. Do not see them going into Phase 111 alone, and there will be more dilution, that is just the nature of a Bio stock.
There are only approx 9 million shares OS, and warrants...so lets say they have 15 million OS all in, that is still fantastic, with little to no debt. Once again Herceptine is 6.7 Bill per year, lets say there is more dilution to the tune of 20 Mill OS. 20 Mill OS x $10 200 mill cap,
I personally think that 30 per share would be a fair valuation, if the science continues to show efficacy in initial Phase 11 data. And 30 per share would only with lets say 20 mill OS give us a 600 mill valuation, far short of a billion, so believe that it will be worth much more than that.
Glynn has executed, everything that he has promised over the years, I am trying to understand how you fail to see all the good that he has brought to TPIV. He has no power over whether the science will pan out in Phase 11/3, but to say that he is not completely invested in TPIV’s success is just not true.
He has attracted good management [considering the science is still an unknown entity] their approach to immunology is completely different than other platforms that have been tested, therefore what I believe to be such speculation in its final success. Their technology is breaking new ground in immunology so we may be 50/50 at this point to find success.
But they have a 3 pronged approach to move forward, Cancer, Infectious disease, and their new Polystart, so we have a much better chance of success if hiccups occur along the way.
If in the next 6 to 12 months, the Phase 11 start to show promise, we will attract the best minds in the industry, Glynn has done much to this point at least it seems that there should be no reason why initial Phase 11’;s won’t be positive.
There will be no Phase 111...they will simply be acquired.
It does seem incredulous that they may have found the holy grail, but if they have indeed found a way to harness the immune system and manipulate it to ones “individual” favour, at such a low cost, it will be invaluable.
I am also nervous at this time as am heavily invested, this is bust or boom at its greatest level, but once again they have various paths moving forward.
Give Glynn some slack, if nothing else he is quite honest, and has got us to this point, I for one would not be anywhere else, he has executed and we now hold the promise of that dedication. And if we lose everything that is simply the nature of investing. But to say that he is unfit is morally and technically not sound.
Once again it is the “science” and not Glynn's execution that will ultimately make TPIV a success!
Best luck to all, as they say “hold the line” the best may yet be to come.
Remember you are sitting on an investment, that holds real promise, embrace the ones that got us here, not ridicule, greater minds than ours, seem to have faith. Look at the glass half full not half empty, that goes for all endeavors in life.
No guarantees in life...no guarantees with investing.
BLU
